A team of researchers led by Brown University infectious disease experts and engineers has identified a new class of antibiotics that could one day help combat the alarming emergence of drug-resistant “superbugs.”
The Dutch regulator has raised concerns about a shortage of narrow-spectrum antibiotics. A lack of targeted therapies is forcing doctors to use broad-spectrum antibiotics that increase the risk of antimicrobial resistance.
Novo Holdings announced the launch of an impact fund with a total budget of $165 million to invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance.
The research project DRIVE-AB has determined that a market entry reward of $1 billion per antibiotic globally could significantly increase the number of new antibiotics coming to the market in the next 30 years
The first-ever Antimicrobial Resistance Benchmark will map the actions of 30 pharmaceutical companies across three research areas: Research & Development, Manufacturing and Production, Access & Stewardship